Bristol Myers Squibb Receives European Commission Approval Of CAMZYOS, For The Treatment Of Symptomatic Obstructive Hypertrophic Cardiomyopathy
CAMZYOS is the first and only cardiac myosin inhibitor approved in the European Union
Approval based on two positive Phase 3 trials, EXPLORER-HCM and VALOR-HCM, demonstrating significant benefit in patients